<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; consider</title>
	<atom:link href="http://www.tapanray.in/tag/consider/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>To restore patients’ confidence MCI has amended its regulations… to strengthen it further will the government consider an Indian version of ‘Physician Payment Sunshine Act’?</title>
		<link>http://www.tapanray.in/to-restore-patients-confidence-mci-has-amended-its-regulations-to-strengthen-it-further-will-the-government-consider-an-indian-version-of-physician-payment-sunshine-act/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=to-restore-patients-confidence-mci-has-amended-its-regulations-to-strengthen-it-further-will-the-government-consider-an-indian-version-of-physician-payment-sunshine-act</link>
		<comments>http://www.tapanray.in/to-restore-patients-confidence-mci-has-amended-its-regulations-to-strengthen-it-further-will-the-government-consider-an-indian-version-of-physician-payment-sunshine-act/#comments</comments>
		<pubDate>Mon, 08 Feb 2010 01:30:08 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[amended]]></category>
		<category><![CDATA[an]]></category>
		<category><![CDATA[Code]]></category>
		<category><![CDATA[confidence]]></category>
		<category><![CDATA[consider]]></category>
		<category><![CDATA[Council]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[further]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[has]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[its]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[MCI]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Payment]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Physician]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulations]]></category>
		<category><![CDATA[restore]]></category>
		<category><![CDATA[strengthen]]></category>
		<category><![CDATA[Sunshine]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[version]]></category>
		<category><![CDATA[Will]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=470</guid>
		<description><![CDATA[In today’s India, blatant commercialization of the noble healthcare services has reached its nadir, as it were, sacrificing the ethics and etiquettes both in medical and pharmaceutical marketing practices at the altar of unlimited greed. As a result of fast &#8230; <a href="http://www.tapanray.in/to-restore-patients-confidence-mci-has-amended-its-regulations-to-strengthen-it-further-will-the-government-consider-an-indian-version-of-physician-payment-sunshine-act/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/to-restore-patients-confidence-mci-has-amended-its-regulations-to-strengthen-it-further-will-the-government-consider-an-indian-version-of-physician-payment-sunshine-act/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>With significant competitive edge should Global Biotech Companies consider entry into high potential ‘Biosimilar drugs’ business?</title>
		<link>http://www.tapanray.in/with-significant-competitive-edge-should-global-biotech-companies-consider-entry-into-high-potential-biosimilar-drugs-business/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=with-significant-competitive-edge-should-global-biotech-companies-consider-entry-into-high-potential-biosimilar-drugs-business</link>
		<comments>http://www.tapanray.in/with-significant-competitive-edge-should-global-biotech-companies-consider-entry-into-high-potential-biosimilar-drugs-business/#comments</comments>
		<pubDate>Thu, 07 May 2009 01:30:20 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[competitive]]></category>
		<category><![CDATA[consider]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[edge]]></category>
		<category><![CDATA[efficacy]]></category>
		<category><![CDATA[entry]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[into]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[potential]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Should]]></category>
		<category><![CDATA[significant]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[with]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=895</guid>
		<description><![CDATA[‘Biosimilar drugs’ – rapid future growth potential: In most of the developed countries of the world, besides regulatory issues, ‘Biosimilar drugs’are considered a threat to the fast growing global biotech industry. However, many believe that innovative biotech companies can have &#8230; <a href="http://www.tapanray.in/with-significant-competitive-edge-should-global-biotech-companies-consider-entry-into-high-potential-biosimilar-drugs-business/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/with-significant-competitive-edge-should-global-biotech-companies-consider-entry-into-high-potential-biosimilar-drugs-business/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
